CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Imbruvica for Mantle Cell Lymphoma (relapsed/refractory)

Project Number PC0073-000
Brand Name Imbruvica
Generic Name Ibrutinib
Strength 140 mg capsule
Tumour Type Lymphoma
Indication Mantle Cell Lymphoma
Funding Request For the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL)
Review Status Complete
Pre Noc Submission No
NOC Date June 24, 2015
Manufacturer Janssen Inc.
Sponsor Janssen Inc.
Submission Date January 29, 2016
Submission Deemed Complete February 5, 2016
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ February 12, 2016
Check-point meeting March 31, 2016
pERC Meeting June 16, 2016
Initial Recommendation Issued June 30, 2016
Feedback Deadline ‡ July 15, 2016
Final Recommendation Issued July 19, 2016
Notification to Implement Issued August 4, 2016
Therapeutic Area Mantle Cell Lymphoma (relapsed/refractory)
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.